Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down – Time to Sell?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY)’s stock price gapped down prior to trading on Friday. The stock had previously closed at $19.97, but opened at $19.33. Chugai Pharmaceutical shares last traded at $20.13, with a volume of 53,023 shares trading hands.

Wall Street Analysts Forecast Growth

CHGCY has been the subject of several recent analyst reports. Nomura raised Chugai Pharmaceutical to a “hold” rating in a report on Tuesday, September 1st. UBS Group lowered Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy”.

Chugai Pharmaceutical Price Performance

The firm has a market cap of $66.63 billion, a PE ratio of 22.00 and a beta of 0.60. The business has a 50-day moving average price of $20.94 and a two-hundred day moving average price of $23.17.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its earnings results on Friday, July 24th. The company reported $0.22 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a return on equity of 23.76% and a net margin of 35.09%. The firm had revenue of $2.14 billion for the quarter, compared to analyst estimates of $2.38 billion. Equities analysts expect that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 earnings per share for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its research focuses on oncology, immunology, neuroscience, hematology and other areas of significant unmet medical need, with capabilities spanning drug discovery, clinical development, manufacturing and commercialization.

Chugai’s portfolio includes medicines such as Actemra (tocilizumab), an immunology treatment; Hemlibra (emicizumab), used to prevent bleeding in people with hemophilia A; and Alecensa (alectinib), a targeted therapy for certain forms of lung cancer.